- Vodori — a leading cloud software provider for life science companies — announced a $7.5 million Series A funding round. These are the details.
Vodori — a leading cloud software provider for life science companies — announced a $7.5 million Series A funding round led by Baird Capital with participation from select existing investors of the company. This news comes less than a year after Vodori launched its sales enablement and analytics solutions that integrate with their content review, approval, and compliance solution Pepper Flow.
Together, these three solutions make up the Pepper Cloud Product Suite: One connected platform of content review, sales enablement, and analytics software that is innovative, life-science focused, and delivered with highly rated customer service. And Pepper Cloud is used by thousands of life science professionals in more than 50 countries worldwide.
Jim Pavlik, a partner with Baird Capital’s Venture Capital team, will join the Board of Directors at Vodori alongside existing Directors Brian Parker, Jim Hussey, Richard Gochnauer, and Scott Rovegno.
KEY QUOTES:
“The Series A financing will empower us to better serve the current and future needs of our life sciences customers. Vodori and Baird Capital share a desire to support innovative pharma and med device companies faced with the need to increase efficiencies as they bring their vital therapies and devices to market. Our long track record in life sciences makes us acutely aware of the fact that healthcare can’t wait. We’re in business to make it easy for life science companies to move fast and get critical care to those who need it most.”
— Scott Rovegno, Vodori CEO and Co-Founder
“We are very excited to partner with the Vodori team and support their mission of accelerating life sciences companies’ commercialization efforts while also ensuring their regulatory compliance. We’ve been extremely impressed by Vodori’s intuitive and flexible suite of cloud-based solutions and look forward to leveraging our firm’s deep expertise and network in the life sciences and B2B software sectors to support the company in its next phase of growth.”
— Jim Pavlik, Partner with Baird Capital’s Venture Capital team
